Moderna (MRNA) - Get Moderna, Inc. Report stock gained on Friday, rising more than 3% in premarket trading, after a U.S. Food and Drug Administration panel gave its approval to a third half-dose booster shot to some Americans to bolster protection against COVID-19.
A panel of advisers to the FDA on Thursday voted unanimously to recommend a booster shot for seniors, adults with other health problems, jobs or living situations that put them at increased risk for COVID.
The 19-0 recommendation is non-binding but an important step toward expanding the U.S. booster campaign to millions more Americans. Many people who got their initial Pfizer (PFE) - Get Pfizer Inc. Report shots at least six months ago are already getting a booster after the FDA authorized their use last month.
The FDA is expected to decide on whether to authorize the booster dose within days. The final nod will come from the Centers for Disease Control and Prevention, which is expected to issue a final recommendation as soon as next week.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.